• In late June 2026, Attunio Health announced a major expansion of its clinical infrastructure by selecting Quest Diagnostics as its national laboratory backbone and integrating Getlabs for at-home blood and genetic testing across the United States.
• Just days earlier, Quest’s Haystack MRD liquid biopsy test gained New York State approval, unlocking nationwide availability for highly sensitive residual cancer detection and reinforcing the company’s position in advanced oncology diagnostics.
• Next, we’ll examine how full U.S. authorization of the Haystack MRD test could influence Quest Diagnostics’ advanced diagnostics-led investment narrative.

Outshine the giants: these 16 early-stage AI stocks could fund your retirement.

Quest Diagnostics Investment Narrative Recap

To own Quest Diagnostics, you need to believe its role as a national “lab backbone” and provider of advanced tests can offset reimbursement pressure, payer mix shifts and rising costs. The Attunio Health partnership and nationwide Haystack MRD availability both support the advanced diagnostics and consumer access catalysts, but they do not fundamentally change the near term focus on pricing headwinds and margin resilience as the key swing factors for the stock.

The Haystack MRD approval in New York, making the liquid biopsy test available in all 50 states, is the most relevant recent development here. It directly supports the thesis that higher value oncology and preventive testing can lift test-per-requisition and reinforce Quest’s advanced diagnostics narrative, even as the company continues to face industry price pressure and potential reimbursement changes.

However, investors should also be aware that if PAMA related reimbursement cuts hit harder or sooner than expected, then...

Quest Diagnostics' narrative projects $13.0 billion revenue and $1.4 billion earnings by 2029.

Uncover how Quest Diagnostics' forecasts yield a $223.44 fair value, a 4% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members put Quest’s fair value between US$223 and US$328 across 2 separate estimates, showing how far apart individual views can be. Against that backdrop, the story around advanced diagnostics growth and persistent reimbursement risk gives you several different angles on how Quest’s performance could evolve, so it is worth comparing multiple perspectives before deciding what you believe.

Explore 2 other fair value estimates on Quest Diagnostics - why the stock might be worth as much as 52% more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Quest Diagnostics research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Quest Diagnostics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Quest Diagnostics' overall financial health at a glance.

Seeking Other Investments?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
• Rare earth metals are the new gold rush. Find out which 30 stocks are leading the charge.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.